PFND.US Pathfinder Cell Therapy Inc
- Market cap
- USD 66.7K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2015.
Is PFND.US undervalued?
Graham numberThe Graham number of Pathfinder Cell Therapy Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pathfinder Cell Therapy Inc fundamental analysis
No fundamental analysis for Pathfinder Cell Therapy Inc yet.
Pathfinder Cell Therapy Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pathfinder Cell Therapy Inc
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered i…
Full company profilePathfinder Cell Therapy Inc financial statements
2015 annualized: Fiscal year 2015 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2015, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pathfinder Cell Therapy Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 142K | 134K | 181K | 360K | 344K | 73.0K | 114K | 54.0K | 0.00 | 0.00 |
| Gross Profit | - | 121K | 105K | 79.0K | 196K | 252K | 47.0K | 64.0K | 17.0K | 0.00 | 0.00 |
| Operating Income | -2.46M | -4.54M | -5.35M | -4.57M | -4.12M | -2.50M | 3.93M | -2.06M | -1.60M | -1.12M | -743K |
| EBITDA | -2.40M | -4.44M | -5.22M | -4.44M | -4.05M | -2.49M | -3.60M | -2.04M | -1.59M | -1.12M | -739K |
| Net Income | -2.15M | -3.90M | -4.62M | -4.40M | -4.10M | -2.08M | -18.9M | -2.25M | -1.81M | -1.67M | -1.36M |
| EPS | -0.03 | -0.05 | -0.05 | -0.05 | -0.04 | 0.00 | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.09M | 4.18M | 3.37M | 3.33M | 1.22M | 145K | 644K | 356K | 155K | 106K | 39.0K |
| Total Liabilities | 956K | 851K | 556K | 428K | 379K | 1.12M | 1.35M | 3.21M | 4.71M | 6.05M | 6.77M |
| Shareholders' Equity | 134K | 3.33M | 2.82M | 2.90M | 842K | -973K | -707K | -2.85M | -4.55M | -5.94M | -6.73M |
| Cash & Short-term Investments | 735K | 3.72M | 2.99M | 2.94M | 963K | 10.0K | 196K | 9.00K | 44.0K | 26.0K | 4.00K |
| Total Debt | 40.0K | 70.0K | - | 8.00K | 7.00K | 462K | 318K | 1.55M | 3.99M | 4.98M | 5.41M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.92M | -2.67M | -3.58M | -3.89M | -3.65M | -1.29M | -2.33M | -2.02M | -1.60M | -963K | -603K |
| Capital Expenditure | 0.00 | 94.0K | 25.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.92M | -2.76M | -3.61M | -3.89M | -3.65M | -1.29M | -2.33M | -2.02M | -1.60M | -963K | -603K |
| Ratios | |||||||||||
| ROE | -1,603.0% | -117.1% | -164.2% | -151.7% | -487.3% | - | - | - | - | - | - |
| ROA | -197.1% | -93.2% | -137.1% | -132.2% | -336.0% | -1,431.7% | -2,938.2% | -632.6% | -1,168.4% | -1,574.5% | -3,476.9% |
| Net Profit Margin | - | -2,743.0% | -3,450.0% | -2,433.1% | -1,139.7% | -603.5% | -25,920.5% | -1,975.4% | -3,353.7% | - | - |
| Debt to Equity | 0.30x | 0.02x | - | 0.00x | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pathfinder Cell Therapy Inc dividends
Pathfinder Cell Therapy Inc has not paid dividends in the last 9 fiscal years.
Who owns Pathfinder Cell Therapy Inc
Ownership data of Pathfinder Cell Therapy Inc is not available yet.
Pathfinder Cell Therapy Inc company profile
- Company name
- Pathfinder Cell Therapy Inc
- Ticker
- PFND.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 12 Bow Street, Cambridge, MA, United States, 02138
- Phone
- 617-245-0289
- Website
- pathfindercelltherapy.com
About Pathfinder Cell Therapy Inc
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Pathfinder Cell Therapy Inc management
3- Mr. Joerg GruberFounder & Chairman · born 1961
- Dr. Richard L. Franklin M.D., Ph.D.Founder, CEO, President, Secretary & Executive Director · born 1945
- Mr. John M. BensonCFO & Treasurer · born 1962